Phase I clinical trials of MRX-115: A new ultrasound contrast agent

Investigative Radiology

Volumn 32, Issue 12, 1997, Pages 735-740

  Fritz, Thomas A ^a   Unger, Evan C ^a,b   Sutherland, George ^c   Sahn, David ^d  

^a ImaRx Therapeutics Inc   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Contrast agents; Echocardiography; Microbubbles; Ultrasound

Indexed keywords

ECHO CONTRAST MEDIUM; LIPID; LIPOSOME; OCTAFLUOROPROPANE; PERFLUTREN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; ECHOCARDIOGRAPHY; ENCAPSULATION; HUMAN; HUMAN EXPERIMENT; INTRAVASCULAR ULTRASOUND; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0031453226     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199712000-00003     Document Type: Article

References (10)

1. Grauer SE, Xu J, Pantely GA, et al. MRX-115, an echocardiographic contrast agent, produces myocardial opacification after intravenous injection in primates: Studies before and after occlusion of left anterior descending coronary artery. Acad Radiol 1996;3:S405-S406.
2. Schneider M, Broillet A, Arditi M, Ventrone R, Puginier I. Doppler intensitometry with BR1, a sonographic contrast agent. Acad Radiol 1996;3:S308-S311.
3. Mattrey RF, Baker KG, Hall LA, Steinbach GC, Peterson T. Placental enhancement with AF0145, a perfluorocarbon-stabilized microbubble sonographic contrast agent. Acad Radiol 1996; 3:S320-S321.
4. Albrecht T, Cosgrove D, Correas JM, Rallidis L, Nihoyanopoulos P, Patel N. Renal, hepatic, and cardiac enhancement on Doppler and gray-scale sonograms obtained with EchoGen. Acad Radiol 1996;3:S198-S200.
5. Fritz T, McKeon M, Unger E. Preclinical studies of MRX-115: Safety evaluations of a myocardial perfusion agent. Acad Radiol 1996;3:S185-S187.
6. Walker KW, Ge J, Grauer S, et al. Echocardiographic imaging of myocardial opacification with second harmonic imaging of peripherally injected Aerosomes® echocontrast yields improved quantitation. J Am Coll Cardiol 1996;27(2 suppl A): 128A.
7. Porter TR, Xie F, Kricsfeld D, Armbruster RW. Improved myocardial contrast with second harmonic transient response imaging in humans using intravenous perfluorocarbon-exposed sonicated dextose albumin. J Am Coll Cardiol 1996;27:1497-1501.
8. Unger EC, Fritz TA. Phase I/II Clinical Trials of MRX-115: A new ultrasound contrast agent. Presented at American Institute of Ultrasound Medicine; March 23-26, 1997; San Diego, CA.
9. Manspeaker P, Fritz T, Gertz EW, Kaul S, Unger E. Preliminary results from a clinical trial in post-infarction patients to assess the optimal dosing technique and echocardiographic imaging parameters for the detection of resting perfusion abnormalities using Aerosomes®. Presented at Contrast Media Research; May 18-22, 1997; Kyoto, Japan.
10. Lindner JR, Firschke C, Wei K, Goodman NC, Skyba DM, Kaul S: Myocardia contrast echocardiography during acute myocardial infarction using intermittent harmonic imaging and intravenous MRX-115. Circulation 1996;94(8 supp):I-575. Abstract.